Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial

Established in 1927 by the American College of Physicians

Abstract/Editors' Note | Full Text | PDF

FIGURES/TABLES SUMMARY PAGE

PowerPoint slides are available for most Figures at Annals.org

Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab

A Randomized Trial

View larger version (26K):
[in this window]
[in a new window]

Figure 1. Study flow diagram.

*Patients with missing Crohn's Disease Activity Index scores were assumed to have had treatment failure.

View this table:
[in this window]
[in a new window]

Table 1. Baseline Characteristics*

View this table:
[in this window]
[in a new window]

Table 2. Patients Achieving Remission at Each Visit*

View larger version (10K):
[in this window]
[in a new window]

Figure 2. Mean Crohn's Disease Activity Index (CDAI) score at each visit.

Remission was defined as a decrease in the CDAI score to <150.

View larger version (16K):
[in this window]
[in a new window]

Figure 3. Summary of subgroup efficacy results.

Differences are reported in percentage points, and error bars represent 95% CIs. Interaction P values were 0.88 for concomitant immunosuppressive therapy (azathioprine, 6-mercaptopurine, and methotrexate), 0.01 for concomitant corticosteroid therapy, 0.52 for previous loss of response to infliximab, 0.28 for previous intolerance of infliximab, 0.17 for previous loss of response to and intolerance of infliximab, 0.36 for presence of antibodies to infliximab at screening, and 0.67 for C-reactive protein (CRP) concentration $≥$ 10 mg/L at week 0. *Missing data for 1 patient in the placebo group. ${dagger}$ Missing data for 7 patients in the placebo group and 6 patients in the adalimumab group.

View this table:
[in this window]
[in a new window]

Table 3. Summary of Safety and Immunogenicity Analyses for All Randomly Assigned Patients*